Index

Note: Page numbers in italics – Tables; Page numbers in bold – Figures

aberrant drug-related behaviors, 143, 150
abuse, 144, 160
deterrent opioids, 160
prevention – 7, 135, 160, 461
substance, 192
ACC, see anterior cingulate cortex
acceptance and commitment therapy (ACT), 380
pain-related avoidance behavior, 380
acceptance/change model
direct support, 380
indirect support, 380
Accreditation Council for Graduate Medical Education (ACGME), 415
competency development, 412
core competencies, 411
post-residency training, 411
ACDs, see anticonvulsant drugs
ACGME, see Accreditation Council for Graduate Medical Education
ACT, see acceptance and commitment therapy
acute pain, 6
behaviors, 19, 20
management, 9
mental disorders, 82
nociceptive system, 6
opioid tolerance, 9
pediatric self-report, 56
phase, 250
and schizophrenia, 90
stimulus generalization, 20
addiction, 144, 160
behaviors, 85
research terms, 144
adjustment disorders
demoralization, 360
distress, 360, 361
preparatory grief, 361
suffering, 361
adjuvants, 143, 368
analgesics, 279
medications, 367
AED, see antiepileptic drugs
affective disorder, 95
Affective Distress scale (AD)
MPI, 101
allodynia, 7, 202
American Pain Society (APS), 474
interdisciplinary professional forum, 415
patient advocacy groups, 415
amygdala function, 253
analogic agents, 9, 132, 144, 150
nonopioid, 5
see also opioids
anesthetics
capsaicin, 368
lidocaine, 368
tocainide, 368
topiramate, 368
anger, 132
exacerbation, 27
hostility, 104
internalization, 27
measures of, 102
in pain development, 95
and pain intensity, 95
see also negative emotions
antagonists, 258
clonidine, 368
antecedent stimulus
categories, 169
anterior cingulate, 210
anterior cingulate cortex (ACC), 202
anticipatory grief, see preparatory grief
anticonvulsant drugs (ACDs), 132, 258, 260, 282
adverse effects, 261
analogic role, 261
carbamazepine, 332
carbazepine, 368
gabapentin, 282, 332, 368
leviracetam, 368
neuromodulatory effects, 261
oxcarbazepine, 368
phenytoin, 368
pregabalin, 332, 368
side effects, 281
topiramate, 332
see also antidepressant
antidepressant, 132, 258, 280
function, 260
neuromodulatory effects, 259
neurotransmitter influence, 259
in pain treatment, 259, 260
working principle, 315
see also opioids
antiepileptic drugs (AED), 343
gabapentin, 345
topiramate, 345
valproate, 345
see also anticonvulsants
anxiety, 26, 88, 107, 132, 192, 220
assessment measures, 98
case example, 87, 88
disorders, 192
duloxetine, 132
FABQ, 98
HADS, 101
and pain, 106
panic disorder, 88
PASS, 98
population studies, 88
PTSD, 26, 88
sensitivity, 192
STAI, 95, 97, 106
tension, 104
TSK, 98
venlafaxine, 132
see also chronic pain; cognitive
errors; depression; negative
emotions
anxiety disorders
in chronic pain, 95
as comorbidity, 350
depression, 87
phobia, 95
anxiety rating scale
HADS, 101
anxiety sensitivity (AS), 27
pain intensity, 27
as predispositional factor, 27
see also anxiety; fears
anxiolytics, 282
APS, see American Pain Society Aquamin, 75
Arnold’s neuralgia, see occipital neuralgia
arthritis
antidepressants, 315
awareness creation, 316
CBT, 317, 319
effect of pain, 314
management, 315
OA, 307
prevalence, 307
psychiatric disorders, 314
psychological therapies, 317
RA, 310
RCTs, 315
SLE, 312
SRTs, 319
AS, see anxiety sensitivity
ascending pain response, 167
attentional focus, 230
diversion, 216
see also hypnosis
attentional strategies
types, 221
see also cognitive coping strategies
attenuated descending analgesic activity, 449
automatic thoughts, 185
biases, 185
avoidant coping, 218
distractions, 218
pain-related variables, 218
performance tasks, 218
azathioprine, 313
back pain
acute, 272
catastrophizing, 25
chronic, 272
low, 272
treatment, 272
types, 276
BDI, see Beck Depression Inventory
BDNF, see brain derived neurotrophic factor
Beck Depression Inventory (BDI), 51, 98, 99, 107
validation, 99
behavioral analysis
functional, 174
behavioral couple therapy
Behavioral Pain Rating Scale (BPRS), 62
Behavioral Pain Scale (BPS), 61
behavioral responses
effects of, 17
behavioral treatment, 180
cognitive, 76
behavioral treatment efficacy, 34, 35
back pain, 34
chronic pain, 34
migraines, 34
behavioral treatment formats
clinic-based treatments, 349
limited contact treatments, 349
no contact treatment, 350
self-management literature, 349
behavioral assessment questionnaire, 173
benzodiazepines, 258, 282
side effects, 282
see also anxiolytics
biofeedback, 33, 176, 209
central, 210
for chronic pain, 33
electromyographic (EMG), 33, 295
heart-rate variability (HRV), 33, 295
mechanism, 33, 211
for migraine, 33
objective, 33
peripheral, 209
recording sensors, 209
rtfMRI, 33
session outline, 209
therapy, 239, 255
types, 208
see also relaxation
biological agents
abatacept, 311
adalimumab, 311
anakinra, 311
etanercept, 311
infliximab, 311
rituximab, 311
biomedical model, 9
pain, 16
biopsychosocial model, 9, 17, 114, 251, 278, 410
application, 470
behavioral medicine, 469
biological factors, 17
chronic conditions, 17
cognitive-behavioral perspective, 470
disease evolution, 17
features, 17
illness expression, 16
implementation, 411
interdisciplinary approach, 11
limitations, 469
misinterpretation, 47
operant behavioral theory, 470
pain, 82
psychogenic factors, 17
psychological components, 252
psychological factors, 278
social components, 252
treatment, 28, 114
BPI, see Brief Pain Inventory
BPRS, see Behavioral Pain Rating Scale
BPS, see Behavioral Pain Scale
central sensitization, 253
treatment, 6, 206
Brief Pain Inventory (BPI), 50, 59, 67, 68
German version, 69
interference dimension, 69
pain intensity scale, 69
pain interference scale, 69, 70
psychometrics, 69
RCTs, 70
scales, 69
validation, 69
buprenorphine, 146
bupropion, 345
C2 neuralgia, see occipital neuralgia
CAM, see Complementary and Alternative Medicine
cancer pain
case example, 88
management, 466
palliative medication, 366
palliative patients, 365, 369
catastrophizing, 224, 237, 251
family members role, 238
catechol-O-methyltransferase (COMT), 448
CB therapy, see Cognitive Behavioral Therapy
CBT, see Cognitive Behavioral Therapy
CDH, see chronic daily headache
Center for Epidemiologic Studies – Depression Scale (CES-D), 99, 107
Cronbach's alpha, 99
validation, 99
central nervous system (CNS), 274
central sensitization, 89, 259, 274
Certified Nurse Practitioners (CNPs), 115
CES, see cranial electrotherapy stimulation
CES-D, see Center for Epidemiologic Studies – Depression Scale
CFR, see Code of Federal Regulations
Checklist of Non-Verbal Pain Indicators (CNPI), 60
Index

chemical pain response, 167
CHEOPS, see Children’s Hospital of Eastern Ontario Pain Scale
child facial coding system, 173
Children’s Hospital of Eastern Ontario Pain Scale (CHEOPS), 57
chronic daily headache (CDH), 340
treatment, 345
chronic opioid therapy, see long-term opioid therapy (LTOT)
chronic pain, 6, 62
alldynia, 202
assessment domains, 450
behavioral treatment, 34
biofeedback, 23, 33
CBT, 454
CDH treatment, 345
in childhood, 190
cognitive shift, 22
conditions causing, 131
drug dosage, 133
drug tolerance, 135
effects, 2, 8, 10, 437, 438
functional analysis, 171
hyperalgesia, 202
“hysteria”, 89
imaging studies, 7
increased longevity impact, 409
insight-oriented approach, 29
interdisciplinary approach, 411
long-term opioid therapy (LTOT), 149
meditation for, 32
mental disorders, 82
vs. migraine, 344
motivational interviewing, 31, 32
negative reinforcement, 22
non-cancer, 9
opioid dependence, 85
opioid tolerance, 135
pain diary, 57
“pain-related” behaviour, 29
patient’s understanding, 22
personal control, 23
pharmacotherapy, 133, 138
physical abnormalities, 20
prescription principles, 133, 134
prevalence, 408, 409
prophylaxis, 345
psychiatric disorders, 96
psychological approach, 29
relaxation, 32
required attitude, 8
self-control, 23
sleep difficulties, 75
social learning mechanisms, 18
syndrome, 174
therapeutic missions, 411
treatment, 29
types, 6
see also breakthrough pain; learning/conditioning behavioral model, interactive
chronic pain comorbidity
fibromyalgia, 344
and headache, 344
and opiates, 345
Chronic Pain Coping Inventory (CPCI), 54
chronic pain phase, 251
Chronic Pain Sleep Inventory, 75
chronic pain, pediatric, 377
acceptance and commitment therapy, 380
acceptance/change model, 380
biopsychosocial model, 379
case study, 387
clinical challenges, 386
functional disability, 381
headache, 377
medications, 377, 378
musculoskeletal pain, 377
PADS, 378
psychosocial treatments, 378
recurrent abdominal pain, 377
rehabilitation literature, 381
rehabilitation model, 378
rules, 382
sick role behavior, 379, 386
clinical best practices
admission, 423, 425
awareness creation, 425
case study, 425
collaborate treatment plan, 425
comfort–function model, 423
comprehensive pain management, 423
pain assessments, 422
substance abuse treatment, 425
Clinical Nurse Specialists (CNSs), 115
clinical trials
adaptive trial design, 453
PBE-CPI, 452
propensity score matching design, 453
RCT, 452
self-management resources, 455
CME, see continuing medical education
CNPI, see Checklist of Non-Verbal Pain Indicators
CNPs, see Certified Nurse Practitioners
CNS, see central nervous system
CNSs, see Clinical Nurse Specialists
Code of Federal Regulations (CFR), 417
codeine, 144
cognitive behavioral model
family members role, 236
Cognitive Behavioral Therapy (CBT), 30, 184, 254, 255, 279, 317, 347, 369
for adults, 191
arthritis, 319
case study, 198
for children, 190
for chronic pain, 118, 184, 185
cognitive restructuring, 185, 245
components, 31, 117, 186, 245
coping skills training, 255
efficacy, 31, 184, 257, 279
family-based therapy, 124, 241, 242
goal completion form, 186
goals, 185
group therapy, 123
impact on physiology, 317
individual therapy, 188
interventions, 369
issues, 188
meta-analysis, 369
modality, 188
multidisciplinary pain management team, 194
pediatric, 239
RCTs, 184, 279
relaxation training, 185
“Stepped Care” approach, 189
techniques, 117
“third generation”, 410
time-based pacing, 185, 186
treatment course, 197
treatment goal, 185
treatment manuals, 188
see also biopsychosocial model; self-regulatory treatments (SRTs)
cognitive coping strategies, 25, 221, 230
active, 25
adaptive, 25
attentional strategies, 216, 218, 221
avoidant coping, 218
clinical treatment studies, 218
cognitive reframing, 225
composites in research, 214
coping self-statements, 227
coping terminologies, 215
cover, 25
discrete, 216
dissociation, 226
effects of ignoring pain, 217
emotional disclosure, 229
empirically derived composites, 214
gender factor in ignoring pain, 217
ignoring pain, 216, 217
imagery, 221
inconsistent findings, 215
individual difference variables, 215
literature review, 216
overt, 25
pain avoidant coping, 220
pain stimulus reinterpretation, 221
pain-related variables, 218
passive, 25
performance tasks, 218
rationally derived composites, 214
reinterpretation, 225
sensory focus, 224
thought suppression, 216
variables in ignoring pain, 217
cognitive errors
anxiety sensitivity (AS), 27
catastrophizing, 25
definition, 24
effects on pain, 24
fears, 26
negative thoughts, 24
post-surgical pain, 24
see also self-efficacy (SE)
cognitive impairment, 193, 362
cognitive reframing, 225
see also reinterpretation
cognitive restructuring, 185, 255
automatic thoughts, 185
bias, 185
worksheet, 187
COMFORT Scale, 57
COMM, see Current Opioid Misuse Measure
communal coping model, 238
pain catastrophizing, 237
in pediatrics, 237
Complementary and Alternative Medicine (CAM), 410
complex regional pain syndrome (CRPS), 328, 377
clinical features, 328
type I, 328
type II, 328
COMT, see catechol-O-methyltransferase
conditions response (CR), 166
see also learning/conditioning behavioral model
conditions stimulus (CS), 166
habituation, 166
US aversive on, 166
see also learning/conditioning behavioral model
Confusion-Bewildenment, 104
Conquering Pain Act of 350, 419
contingency management – operant behavioral (OB) therapy
application guidelines, 175
indicators, 174
continuing medical education (CME), 474
coping self-statements, 227, 230
correlational research, 226
variables, 226
coping skills training, 255
cortical pain response, 167
cortical stimulation, 204
CES, 205
tDCS, 205
CPOT, see Critical-Care Pain Observation Tool
CR, see conditions response, 166
cranial electrotherapy stimulation (CES), 205
Critical-Care Pain Observation Tool (CPOT), 62, 173
Cronbach's alpha, 99
CRPS, see complex regional pain syndrome
CS, see conditions stimulus
Current Opioid Misuse Measure (COMM), 154
cyclophosphamide, 313
cyclosporine A, 313
daily activity diary, 173
DEA, see Drug Enforcement Administration
Dehydroepiandrosterone (DHEA), 314
delirium, 362
impact, 362
prevalence, 362
demented patients, 362
emotional responsivity, 362
dementia, 91
demoralization, 360
coping mechanism, 360
vs. depression, 360
development, 360
and factor analysis, 360
prevalence, 360
denial, 363
depression, 26, 87, 191, 291, 358
and ageing, 392
anxiety disorders, 87
BDI, 99
CES-D, 99
clinical studies, 86
comorbidity, 87
dejection, 104
discrete symptoms, 107
duloxetine, 132
features, 360, 361
GDS, 101
HADS, 101
HAM-D, 100
impact on pain management, 399
opioid, 87
prevalence, 360
reasons for, 95
self-report measures, 96
venlafaxine, 132
Zung SDS, 100
see also anxiety; chronic pain; cognitive errors
depression rating scale
BDI, 99
CES-D, 99
Cronbach's alpha, 99
GDS, 101
HADS, 101
HAM-D, 100
Zung SDS, 100
descending noxious inhibitory control (DNIC), 449
descending pain response, 167
DHEA, see Dehydroepiandrosterone Diagnostic Interview Schedule (DIS), 104, 105
diathesis-stress model, 83, 192
dihydrocodeine, 144
disease modifying anti-rheumatic drugs (DMARD), 311
dissociation, 226, 230
distancing, see sensory focus
distraction, 230
distractions, 144, 218, 219
distress, 360
diversion, 144
DMARD, see disease modifying anti-rheumatic drugs
DNIC, see descending noxious inhibitory control
doctor–patient relationship, 137
DOLUPLUS-2, 60
drug “schedules”, 462
Drug Enforcement Administration (DEA), 414, 426
drug-opposite effect, 84
duloxetine, 132
dysesthesia, 276
dysphoric symptoms, 360
EEG, see Electroencephalography
EFT, see Emotionally Focused Therapy
electroencephalography (EEG), 203
see also biofeedback; neurofeedback
emotion focus, 221
see also sensory focus
Index

emotional disclosure, 229, 230
  efficacy, 227
  emotional variables, 228
  heart rate habituation, 228
  interpersonal relationships, 228
  negative emotion words, 228
  pain catastrophizing, 228
  pain related variables, 228
  emotional distress
    anxiety, 107
    assessment measures, 97
    dimensions of, 105, 106
    and pain interventions, 105
    in pain treatment, 105
    POMS, 106
    recommendations for CPA, 107
    single item measures, 96
  emotional expressive therapy, 367
  emotional functioning
    assessment necessity, 94
    comprehensive pain assessment, 96
    dimensions, 95
    MMPI, 102
    negative emotions, 94
    POMS, 106
  Emotionally Focused Therapy (EFT), 244
  emotions, 95
  "state", 95
  "trait", 95
  end-of-life care, 416, 417
  endorphin, 28
  EPCA-2, 173
  epidural analgesia, 9
  Epworth Sleepiness Scale, 335
  equianalgesic conversion table, 146
  dose conversion, 146, 147
  limitations, 146
  erythrocyte sedimentation rate (ESR)
    test, 312
  escape – avoidance conditioning, 168
  see also learning/conditioning
  behavioral model
evidence-based algorithm, 135
  exercises, 74
  Baduanjin, 75
  leg-flexion, 75
  existential distress, 361
  spiritual pain, 361
  exposure/desensitization, 176
  expressive writing, 227, 230
  see also emotional disclosure
  extinction paradigm, 168
  see also learning/conditioning
  behavioral model
  extractability, 160
  dimensions of, 160
  FABQ, see Fear-Avoidance Beliefs
  Questionnaire
  Face, Legs, Activity, Cry, Consolability
    (FLACC), 57
  Faces Pain Scale (FPS), 58
  Revised (FPS-R), 56
  family-based therapy, 240, 241, 242
  family systems models, 237, 241
  fatigue-inertia, 104
  fear-avoidance, 255
  Fear-Avoidance Beliefs Questionnaire
    (FABQ), 98
  fears
    role in pain, 28
    feelings state pain response, 167
  fentanyl, 146, 161
  fibromyalgia (FM), 344
  assessment, 450
  pain management, 5
  stimulus-induced activity, 449
  fibromyalgia syndrome (FMS), 286
  ACR criteria, 287
  classification criteria, 287, 288
  compensation issues, 290
  empirically driven criteria, 287
  etiology, 286
  functional disability, 289
  healthcare utilization, 289
  history, 288
  immunological vulnerability, 292
  multidisciplinary, 296
  muscle tension, 291
  "Muskelkriechöl", 286
  neurotransmitters, 292
  pain modulation, 292
  pathophysiology, 292
  patient's information, 297
  psychological disorder, 291
  responses, 298
  sleep disorder, 291
  Smythe's criteria, 287
  stressors, 292
  tender points (TPs), 288
  treatment, 296
  treatment results, 297
  work disability, 290
  "fibrosistic nodules", 286
  fifth vital sign, 393
  FLACC, see Face, Legs, Activity, Cry,
  Consolability
  GMI, see functional MRI
  FMS pharmacological treatment, 294
  anesthetics, 294
  antidepressant, 293
  antiepileptic drugs (AEDs), 294
  anti-inflammatory drugs, 293
dopamine agonist, 294
  growth hormone, 294
  opioids, 293
  sedatives, 293
  SSRI, 293
  TCAs, 293
  FMS, see fibromyalgia syndrome
  foramen, 272
  functional behavioral analysis, 178,
  179
  functional disability, 386
  biopsychosocial rehabilitation, 380
  sick role behavior, 380
  functional MRI (fMRI)
    uses, 451
  functional status, 358
  and depression, 358
  impact on psychology, 358
  and pain, 358
  Gabapentin, 9
  gate control theory, 44, 190, 204
  neurobiological model, 447
  see also neuromodulation
  GCH1, see GTP cyclohydrolase
  GDS, see Geriatric Depression
  Scale
  GDTA, see goal-directed therapy
  agreements
  Georgia Comprehensive Sickle Cell
  Center, 423
  Geriatric Depression Scale (GDS), 51,
  59, 101
  Cronbach's alpha, 101
  questionnaire, 101
  versions of, 101
  geriatric pain
    effects, 437
    prevalence, 437
  Geriatric Pain Measure (GPM), 59
  goal-directed therapy agreements
    (GDTA), 149, 156
  see also goal-oriented management
  plan; pharmacotherapy
  goal-oriented management plan, 136,
  138
  GPM, see Geriatric Pain Measure
  grief process, 361
  group therapy, 177, 368
  advantages, 187, 191
  GTP cyclohydrolase 1 (GCH1), 448
guided imagery, 34, 255
  visualization role, 33
  see also imagery; relaxation
habitation, 166
HADS, see Hospital Anxiety and Depression Scale
HAM-D, see Hamilton rating scale for depression
Hamilton Depression Inventory (HDI), 99
Hamilton rating scale for depression (HAMD), 99, 100
Harm Avoidance, 90
HDI, see Hamilton Depression Inventory
headache, 339
AED as prophylaxis, 343
behavioral treatment, 346, 347, 348, 349, 350
beta blockers as prophylaxis, 343
biofeedback behavioral therapy, 347
CBT, 347, 350
CDH, 340, 345
comorbidity, 339, 340, 341
economic impact, 340
hemichromia continua, 340
interventional therapies, 343
long-lasting, 340
medication compliance, 350, 351
MOH, 341
new daily persistent, 340
pressure related, 341
prevalences, 339
primary, 340
prophylaxis, 343, 345
refractory, 345
relaxation behavioral therapy, 347
SIH, 341
tension-type, 340
treatment regimen, 342
treatment failure, 346
triglyceride antidepressants as prophylaxis, 343
trigger factors, 347
headache, tension-type
behavioral therapy, 349
behavioral vs. drug therapy, 349
comorbidity, 350
headaches, cluster, 330
chronic, 330
criteria for, 330
episodic, 329
health care disparities, 436, 437, 438, 439, 440, 441
population projection, 434, 435
providers, 1, 124
socio-demographic factors in, 434
heart rate habituation, 228
hemichromia continua, 340
treatment, 341
herpes zoster, 7
see also varicella zoster virus (VZV)
HIV neuropathy, 149
H-MRS, see proton magnetic resonance spectroscopy
hope, 361
Hospital Anxiety and Depression Scale (HADS), 101
Cronbach's alpha, 101
self-report measure, 101
subscales, 101
human rights and pain treatment, 417
hydrocodone, 144, 146
hydromorphone, 145, 146
hyperalgesia, 7, 202, 276
hyperesthesia, 276
hypothalamic, see hyperalgesia
hypnosis, 34, 255, 369
action mechanism, 207
advantages, 207
case study, 208
for chronic pain, 206, 208
components, 34
hypno-anesthesia, 206
hypnotic experience, 206
induction, 206
mode of use, 34
osteoarthritis, 319
pain characteristics assessment, 206
as pain control, 34
response variabilities, 207
self, 206
sensory substitution, 206
see also attentional focus
IASP, see International Association for the Study of Pain
iatrogenic addiction, 461
response, 144
IBCT, see integrative behavioral couple therapy
IBQ, see Illness Behavior Questionnaire
idiopathic intracranial hypertension (IIH), 341
IFP, see Individualized Functional Plan
ignoring pain, 216, 217, 230
effects of, 217
gender factor in, 217
variables in, 217
IIH, see idiopathic intracranial hypertension
illness, 16
behaviors, 19
expression, 16
see also disease
Illness Behavior Questionnaire (IBQ), 103
scales, 103
imagination pain response, 167
IMMPACT (Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials)
groups, 45
individual therapy, 188
Individualized Functional Plan (IFP), 382, 384
informed consent opioids, 155, 157
insight-oriented therapy, 241
integrative behavioral couple therapy (IBCT), 243, 245
see also spouse-assisted coping skills training (S-CST)
Interdisciplinary Pain Rehabilitation Programs (IPRPs), 117
addiction treatment, 120
biofeedback therapist's role, 116
candidate selection, 120, 121, 122
challenges, 126
chronic condition treatment, 121
CNPs and CNP's role, 115
cmprensive treatment, 118
efficacy, 125
family therapy, 124
group therapy, 124
medication management, 118
nurse care coordinator's role, 115
objective, 117
occupational therapist's role, 116
opioid withdrawal, 119
pain conditions, 120, 125
psychologist's role, 115
pain treatment, 117, 121
patient characteristics, 121
patient's care, 117
physical therapist's role, 116
physician's role, 115
rehabilitation progress, 124
"rolling admission" group, 124
services, 122
treatment approach, 117
treatment intensity, 122
treatment team, 114
vocational specialist's role, 116
see also biopsychosocial model; Cognitive Behavioral Therapy
International Association for the Study of Pain (IASP), 415
interpersonal therapy, 255
<table>
<thead>
<tr>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>intervertebral discs, 274</td>
</tr>
<tr>
<td>intra-articular injection</td>
</tr>
<tr>
<td>OA, 309</td>
</tr>
<tr>
<td>intractable pain therapy acts (IPTAs), 418</td>
</tr>
<tr>
<td>IPRPs, see Interdisciplinary Pain Rehabilitation Programs</td>
</tr>
<tr>
<td>IPTAs, see intractable pain therapy acts</td>
</tr>
<tr>
<td>JCAHO, see Joint Commission on Accreditation of Healthcare Organizations (JCAHO)</td>
</tr>
<tr>
<td>Joint Commission on Accreditation of Healthcare Organizations (JCAHO), 415, 418</td>
</tr>
<tr>
<td>pain-related standards, 48</td>
</tr>
<tr>
<td>&quot;jump sign&quot;, 286</td>
</tr>
<tr>
<td>kinesiophobia, 335, see (pain-related fear)</td>
</tr>
<tr>
<td>knee OA, 307</td>
</tr>
<tr>
<td>lamellae, 274</td>
</tr>
<tr>
<td>LAO, see long-acting opioids</td>
</tr>
<tr>
<td>law vs. guidelines, 417</td>
</tr>
<tr>
<td>LCPA, see Liaison Committee on Pain and Addiction</td>
</tr>
<tr>
<td>learning/conditioning behavioral model, 166</td>
</tr>
<tr>
<td>behavioral assessment, 172</td>
</tr>
<tr>
<td>behavioral treatment, 180</td>
</tr>
<tr>
<td>case study, 181</td>
</tr>
<tr>
<td>effects on pain responses, 171</td>
</tr>
<tr>
<td>exposure – desensitization, 176</td>
</tr>
<tr>
<td>functional behavioral analysis, 178, 179</td>
</tr>
<tr>
<td>group therapy, 177</td>
</tr>
<tr>
<td>in pain management, 172</td>
</tr>
<tr>
<td>interactive, 169, 171</td>
</tr>
<tr>
<td>interdisciplinary treatment, 179 observational, 169</td>
</tr>
<tr>
<td>observational based therapy, 177 operant, 169</td>
</tr>
<tr>
<td>operant conditioning therapeutics, 176 overt pain behaviors, 173</td>
</tr>
<tr>
<td>pain functional analysis, 170 Pavlovian B conditioning, 176</td>
</tr>
<tr>
<td>progressive muscle relaxation, 176</td>
</tr>
<tr>
<td>required research, 181 respondent, 167</td>
</tr>
<tr>
<td>respondent based therapy, 176 respondent conditioning effects, 171 levorphanol, 145</td>
</tr>
<tr>
<td>Liaison Committee on Pain and Addiction (LCPA), 143</td>
</tr>
<tr>
<td>lidocaine, 132 lithium, 258 long-acting opioids (LAO), 345</td>
</tr>
<tr>
<td>long-term opioid therapy (LTOT), 150 agreement, 159 for chronic pain, 149 documentation, 151 GDTA, 149 informed consent, 155, 157 NOSE, 151 risk management elements, 155 UDT, 155 universal precautions, 155 LTOT, see long-term opioid therapy</td>
</tr>
<tr>
<td>Major Depressive Disorder (MDD) diagnosis, 96 &quot;maldynia&quot;, see (chronic pain)129 MBHI, see Millon Behavioral Health Inventory McGill Pain Questionnaire (MPQ), 51, 52 medical prescribers' protection, 418 guidelines, 417 JCAHO, 418 levels of legality, 417 nonpharmacologic treatments, 418 state-level medical boards, 417 &quot;medically unexplained symptoms&quot;, see somatoform pain disorder medication &quot;cocktails&quot;, 118 side effects, 118 see also polypharmacy medication overuse headache (MOH), 342 treatment, 342 medico-social emergency, 407, 409 meditation, 32, 33 alpha brainwave activity, 32 for chronic pain, 32 forms of, 32 gamma brainwave activity, 32 health benefits, 32 mindfulness, 32 transcendental, 32 meditations, 409 metaphysical paradox, see mind-body problem methadone, 84, 145 methadone(b), 146 migraine, 329, 341 behavioral therapy, 348 behavioural vs. drug therapy, 348 biofeedback, 33 CDH progression, 341 vs. chronic pain, 344 comorbidity, 350 criteria for, 329 diagnosis of episodic, 340 economic impact, 339, 340 headaches, 329 lifetime prevalence, 342 and opioids, 345 pain management, 5 personal control, 23 personality, 27 preventable, 341 preventive therapies, 342 refractory, 343, 344 role of comorbidities, 340 unpreventable, 341 Millon Behavioral Health Inventory (MBHI), 53 psychological functioning assessment, 103 mind-body connection, 410 mind-body problem, 409 mindfulness-based strategies, 223 Minnesota Multiphasic Personality Inventory (MMPI), 102 in coping assessment, 102 Minnesota Multiphasic Personality Inventory (MMPI-2), 102 clinical scales, 102 vs. NTI, 102 misuse, 144 mitrazapine, 259 MMPI, see Minnesota Multiphasic Personality Inventory moderators, 35 MOH, see medication overuse headache mood disorders as comorbidity, 350 mood stabilizers, see antidepressant drugs morphine, 146 morphine sulphate, 145 motivational interviewing, 31, 32 &quot;action&quot; stage, 31 &quot;contemplation&quot; stage, 31 &quot;maintenance&quot; stage, 31 &quot;preparation&quot; stage, 31 MPI, see Multidimensional Pain Inventory MPQ, see McGill Pain Questionnaire Multidimensional Pain Inventory (MPI), 72, 101, 173 Affective Distress scale (AD), 101 Multidimensional Pain Readiness to Change Questionnaire (MPRCQ), 55 pain coping strategies, 55 two-factor structure, 55 multidisciplinary pain center (MPC), 421–22 muscle hypertonicity, 28 cognitive factors, 28 &quot;Muskelchwiele&quot;, 286 narcotic, 143 National Pain Care Act of 350, 419</td>
</tr>
<tr>
<td>Term</td>
</tr>
<tr>
<td>-------------------------------------------</td>
</tr>
<tr>
<td>Negative Treatment Indicators (NTI)</td>
</tr>
<tr>
<td>neuropathic pain</td>
</tr>
<tr>
<td>neuralgia</td>
</tr>
<tr>
<td>neurofeedback (NF)</td>
</tr>
<tr>
<td>anterior cingulate</td>
</tr>
<tr>
<td>efficacy</td>
</tr>
<tr>
<td>QEEG, 210</td>
</tr>
<tr>
<td>targets for, 210</td>
</tr>
<tr>
<td>see also biofeedback</td>
</tr>
<tr>
<td>electroencephalography (EEG)</td>
</tr>
<tr>
<td>neuroglia</td>
</tr>
<tr>
<td>neuromatrix model</td>
</tr>
<tr>
<td>neuromodulation</td>
</tr>
<tr>
<td>cortical reorganization</td>
</tr>
<tr>
<td>electrical stimulation</td>
</tr>
<tr>
<td>electroencephalography</td>
</tr>
<tr>
<td>non-pharmacological</td>
</tr>
<tr>
<td>see also pain management</td>
</tr>
<tr>
<td>neuropathic pain (NP)</td>
</tr>
<tr>
<td>allodynia</td>
</tr>
<tr>
<td>characteristics</td>
</tr>
<tr>
<td>CNS hyperexcitability</td>
</tr>
<tr>
<td>CRPS, 328</td>
</tr>
<tr>
<td>diagnosis</td>
</tr>
<tr>
<td>headache syndromes</td>
</tr>
<tr>
<td>hyperalgies</td>
</tr>
<tr>
<td>“injury discharge”</td>
</tr>
<tr>
<td>ionic channels expression</td>
</tr>
<tr>
<td>neuralgia</td>
</tr>
<tr>
<td>neuroglia</td>
</tr>
<tr>
<td>neuron damage</td>
</tr>
<tr>
<td>neuropathy</td>
</tr>
<tr>
<td>occipital neuralgia</td>
</tr>
<tr>
<td>opioids</td>
</tr>
<tr>
<td>pathophysiology</td>
</tr>
<tr>
<td>symptoms</td>
</tr>
<tr>
<td>syndromes</td>
</tr>
<tr>
<td>treatment</td>
</tr>
<tr>
<td>tricyclic antidepressants</td>
</tr>
<tr>
<td>trigeminal neuralgia</td>
</tr>
<tr>
<td>neuropathy</td>
</tr>
<tr>
<td>syndromes</td>
</tr>
<tr>
<td>neurotransmission inhibitors, 258</td>
</tr>
<tr>
<td>NNH, see number needed to harm</td>
</tr>
<tr>
<td>NNT, see number needed to treat</td>
</tr>
<tr>
<td>nociception</td>
</tr>
<tr>
<td>nociceptive pain</td>
</tr>
<tr>
<td>nociceptive system</td>
</tr>
<tr>
<td>central sensitization</td>
</tr>
<tr>
<td>information transfer, 201, 202</td>
</tr>
<tr>
<td>peripheral sensitization</td>
</tr>
<tr>
<td>nociceptors</td>
</tr>
<tr>
<td>non-opioid medications</td>
</tr>
<tr>
<td>Non-Communicative Patient’s Pain Assessment Instrument (NOPPAIN), 60</td>
</tr>
<tr>
<td>nonpharmacologic therapy</td>
</tr>
<tr>
<td>nonsteroidal anti-inflammatory drugs</td>
</tr>
<tr>
<td>non-terminal pain medication</td>
</tr>
<tr>
<td>non-verbal pain response</td>
</tr>
<tr>
<td>NOPPAIN, see Non-Communicative Patient’s Pain Assessment Instrument</td>
</tr>
<tr>
<td>norepinephrine and dopamine</td>
</tr>
<tr>
<td>see also antidepress</td>
</tr>
<tr>
<td>normal pain</td>
</tr>
<tr>
<td>see nociceptive pain</td>
</tr>
<tr>
<td>NOSE, see Numerical Opioid Side Effect</td>
</tr>
<tr>
<td>NP, see neuropathic pain</td>
</tr>
<tr>
<td>NRS, see numeric rating scale</td>
</tr>
<tr>
<td>NSAIDs, see nonsteroidal anti-inflammatory drugs</td>
</tr>
<tr>
<td>NTT, see Negative Treatment Indicators</td>
</tr>
<tr>
<td>nucleus pulposus</td>
</tr>
<tr>
<td>number needed to harm</td>
</tr>
<tr>
<td>number needed to treat</td>
</tr>
<tr>
<td>numeric rating scale</td>
</tr>
<tr>
<td>Numerical Opioid Side Effect</td>
</tr>
<tr>
<td>OA, see osteoarthritis</td>
</tr>
<tr>
<td>OB therapy</td>
</tr>
<tr>
<td>see operant behavioral</td>
</tr>
<tr>
<td>OB therapy</td>
</tr>
<tr>
<td>observational basis therapy, 177</td>
</tr>
<tr>
<td>occipital neuralgia</td>
</tr>
<tr>
<td>OMERACT, see Outcomes Measures in Rheumatology</td>
</tr>
<tr>
<td>OMS, see Opioid Management Society</td>
</tr>
<tr>
<td>operant behavioral (OB) therapy</td>
</tr>
<tr>
<td>application guidelines, 175</td>
</tr>
<tr>
<td>operant behavioral theory, 470</td>
</tr>
<tr>
<td>operant conditioning</td>
</tr>
<tr>
<td>indicators, 174</td>
</tr>
<tr>
<td>in pain treatment, 172</td>
</tr>
<tr>
<td>operant model</td>
</tr>
<tr>
<td>family members role, 236</td>
</tr>
<tr>
<td>opiates, 143</td>
</tr>
<tr>
<td>LAO, 345</td>
</tr>
<tr>
<td>refractory headache, 345</td>
</tr>
<tr>
<td>opioid</td>
</tr>
<tr>
<td>abuse, 87</td>
</tr>
<tr>
<td>effects, 87</td>
</tr>
<tr>
<td>in geriatric, 393, 394</td>
</tr>
<tr>
<td>mu opioid receptor, 89</td>
</tr>
<tr>
<td>opioid dependence, 84</td>
</tr>
<tr>
<td>case report, 86</td>
</tr>
<tr>
<td>chronic pain, 85</td>
</tr>
<tr>
<td>depression, 87</td>
</tr>
<tr>
<td>see also addiction, opioid therapy</td>
</tr>
<tr>
<td>Opioid Management Society (OMS), 142</td>
</tr>
<tr>
<td>opioid risk tool (ORT), 154</td>
</tr>
<tr>
<td>opioid rotation, 145</td>
</tr>
<tr>
<td>aims of, 145</td>
</tr>
<tr>
<td>factors considered, 147</td>
</tr>
<tr>
<td>indications for, 145</td>
</tr>
<tr>
<td>principle, 145</td>
</tr>
<tr>
<td>opioid therapy, 84</td>
</tr>
<tr>
<td>documentation, 151</td>
</tr>
<tr>
<td>downhill spiral hypothesis, 85</td>
</tr>
<tr>
<td>“drug-opposite” effect, 84</td>
</tr>
<tr>
<td>first-line therapy, 149</td>
</tr>
<tr>
<td>methadone, 84</td>
</tr>
<tr>
<td>SAFE score, 153</td>
</tr>
<tr>
<td>substance use, 85</td>
</tr>
<tr>
<td>see also addiction, opioid-induced hyperalgesia, 84</td>
</tr>
<tr>
<td>see also opioid therapy</td>
</tr>
<tr>
<td>opioids, 132, 137, 142, 143, 145, 367</td>
</tr>
<tr>
<td>aberrant drug-related behaviors, 143</td>
</tr>
<tr>
<td>abuse, 119</td>
</tr>
<tr>
<td>abuse prevention, 4, 461</td>
</tr>
<tr>
<td>abuse-deterrent, 160</td>
</tr>
<tr>
<td>administration routes, 148</td>
</tr>
<tr>
<td>adverse effects prevalence, 148</td>
</tr>
<tr>
<td>“balance”, 142</td>
</tr>
<tr>
<td>chronic pain, 466</td>
</tr>
<tr>
<td>chronic therapy, 149</td>
</tr>
<tr>
<td>clinical studies, 148</td>
</tr>
<tr>
<td>contracts elements, 155</td>
</tr>
<tr>
<td>conversion, 147</td>
</tr>
<tr>
<td>dosage, 144</td>
</tr>
<tr>
<td>drug ‘schedules’, 462</td>
</tr>
<tr>
<td>efficacy, 10, 148</td>
</tr>
<tr>
<td>at end of life, 465</td>
</tr>
<tr>
<td>endogenous, 28</td>
</tr>
<tr>
<td>equianalgesic conversion table, 146</td>
</tr>
<tr>
<td>ethical issue, 459</td>
</tr>
<tr>
<td>fentanyl patch, 332</td>
</tr>
<tr>
<td>first-line therapy issues, 149</td>
</tr>
<tr>
<td>in FM, 293, 454</td>
</tr>
<tr>
<td>health concern, 161</td>
</tr>
<tr>
<td>health issue, 414–15</td>
</tr>
<tr>
<td>HIV neuropathy, 149</td>
</tr>
<tr>
<td>hydromorphone, 368</td>
</tr>
<tr>
<td>hyperalgesia, 10</td>
</tr>
<tr>
<td>iatrogenic addiction, 461</td>
</tr>
<tr>
<td>issues, 462, 466, 473</td>
</tr>
<tr>
<td>management, 10, 11</td>
</tr>
<tr>
<td>mechanisms of, 142</td>
</tr>
<tr>
<td>methadone, 332, 347, 368</td>
</tr>
<tr>
<td>morphine, 332, 368</td>
</tr>
</tbody>
</table>
Index

opioids (cont.)
- narcotic, 143
- neuropathic pain, 331
- NNH, 148
- opiates, 143
- ORT, 154
- osteoarthritis (OA), 309
- oxycodone, 368
- oxymorphone, 145, 146
- pain severity, 143
- palliative care, 462
- patient safety, 461
- POPP associated activities, 149
- pseudoaddiction, 143
- pseudotolerance, 143
- receptor, 142
- recommendation, 413
- regulation, 161, 413
- risk management, 154
- screener and assessment, 153
- screening tools, 148
- second-line therapy, 148
- side effects, 368
- SISAP, 153
- SOAPP, 154
- spinal administration, 148
- synergistic effect, 367
- tolerance, 133
- toxicity, 145
- tramadol patch, 332
- transdermal administration, 147
- treatment, 118, 144
- opiophobia, 418
- ORT, see opioid risk tool
- osteoarthritis (OA), 307, 308
- causes, 308
- CBT, 319
- depression, 314
- diagnosis, 308
- hypnosis, 319
- inflammatory mediators, 308
- intra-articular injection, 309
- knee OA, 307
- non-pharmacologic treatments, 309
- osteophytes, 307
- pharmacologic treatments, 309
- relaxation training, 319
- SRTs, 319
- surgery, 309
- symptoms, 308
- synovial fluid analysis, 308
- see also rheumatoid arthritis (RA); systemic lupus erythematosus (SLE)
- osteoarthropathies, 307
- Oucher pain scale, 56
- Outcomes Measures in Rheumatology (OMERACT ), 450
- IMMPACT, 450
- WHO-ICE, 450
- overmedication, 418
- overt pain behavior rating system, 173
- overt pain behaviors, 173
- oxycodone, 145, 146
- oxymorphone, 145, 146
- PACSLAC, see Pain Assessment Checklist for Seniors with Limited Ability to Communicate
- PADS, see Pain-Associated Disability Syndrome
- PADT, see Pain Assessment and Documentation Tool
- acute, 6
- adult expressions, 59
- affective factor, 25, 33396
- allodynia, 278, 448
- analgesic selection, 144
- anterior cingulate role, 210
- anticipated pain, 22
- anticipatory anxiety, 20
- attitude effect, 46
- avoidance behavior, 20
- behavioral definition, 165, 460
- behavioral response model, 166
- benign, 129
- biofeedback therapy, 33
- biomedically-based conceptualizations, 250
- biopsychosocial model, 17, 35
- brain regions, 203
- in cancer, 3, 129
- catastrophizing, 83, 120
- central pain, 449, 450
- chronic, 6
- cognitive coping strategies, 21, 35, 215
- cognitive factors, 21, 22, 331
- complicated disorders, 115
- components, 44
- control by brain, 35
- desired reduction level, 8, 9
- diagnosis, 4, 5
- dimensions, 5, 131
- effects, 28, 48, 49, 60
- and emotion, 96
- epidemiology, 408
- factors, 18, 20, 190, 191, 203, 363, 449
- as fifth vital sign, 4, 11, 424
- function, 3, 274, 459
- functional MRI, 449
- gate control theory, 63, 447
- health care provider’s beliefs, 22
- history, 276, 447
- hyperalgesia, 278, 448, 449
- ignoring pain, 217
- imaging studies, 203
- indicator of, 5
- intensity, 28
- interpretations, 23
- learned expectation, 22
- learning/conditioning behavioral model, 166
- levels of, 69
- measures, 276
- mechanistic characterization scheme, 449, 450
- modulation, 203
- muscle hypertonicity, 28
- musculoskeletal examination, 278
- negative reinforcement, 22, 50
- neuromatrix model, 202, 252
- neuropathy physical examination, 278
- nociceptive pain, 450
- normal, 6
- operant formulation, 19
- opioid treatment, 144
- origin, 16
- palliative care, 355, 356
- pathological, 6
- patient self-report, 47
- patient’s interpretations, 21, 22
- personal control, 23
- physical examination, 278
- physical therapy, 178
- physiological, 6, 460
- psychology of, 202, 257
- postoperative, 3
- psychiatric disorders, 82, 83
- psychogenic, 5, 28, 89, 249
- psychosocial approach, 35
- respondent learning mechanisms, 20
- responses, 5, 20, 67, 167, 170, 179, 180
- and self-efficacy, 371
- signal processing, 333
- skin examination, 276
- and sleep, 335, 393
- socioeconomic disadvantage, 4
- somatic, 249
- spinal physical examination, 278
- stimulus, 20
- stress and, 253
- as survival tool, 27
- transition, 132
- transmission, 203
- types, 5, 6, 274, 407
- undertreatment, 409
- vulnerability, 439
- Pain Anxiety Symptom Scale (PASS), 51, 98
- pain as fifth vital sign, 4, 11, 424
- limitations, 471
pain assessment, 44, 470
adult behavioral measures, 60
adult non-verbal cognitively impaired, 62
“analgesic ladder” approach, 143
biopsychosocial aspect, 44, 45
challenges, 473
CNPI for adult, 60
cognitive impairment impact, 57
communication, 439
on dimensions, 131
DOLUPLUS-2 for adult, 60
in elderly persons, 60
electroencephalography, 203
fMRI limitation, 202
funding, 473
gate control theory, 44
limited ability adult, 60
misinterpretations expressions, 62
non-verbal adult, 60, 61, 62
NOPPAIN for adult, 60
objectives, 46
pain transition indicator, 453
PAINAD-2 for adult, 60
patient interview, 49
principles, 45
provider behavior, 58
psychiatric diagnosis, 453
Pain Assessment and Documentation Tool (PADT), 151
Pain Assessment Checklist for Seniors with Limited Ability to Communicate (PACSLAC), 60
Pain Assessment in Advanced Dementia (PAINAD), 60, 173
pain behaviors, 18, 19, 124, 470
acute, 19
anger, 27
anticipatory fear, 30
avoidance, 29
in children, 18, 19, 190
negative reinforcement, 29
non-reinforced, 30
operant conditioning, 30
operant learning mechanisms, 19
physician-patient behavior, 30
positive reinforcement, 29
respondent conditioning, 30
social learning mechanisms, 19
spouses’ responses, 19
“well-behaviors”, 30
pain behaviour check-list, 173
pain beliefs, 54
pain care barriers, 440
categories, 416
chronic pain, 10
disparities, 472
interdisciplinary, 10
multidisciplinary pain center, 421–2
perceptions, 440
pain catastrophizing, 237
communal coping model, 237
solicitous responses, 237
pain centers, multidisciplinary, 10
pain comprehensive assessment, 45
awareness creation, 45
biopsychosocial aspect, 45
challenges, 47
outcome assessment criterion, 45
pain as fifth vital sign, 47
pain beliefs, 54
treatment planning, 45
pain coping assessment, 53
categories, 54
CPCI, 54
pain crisis, 372
pain diary, 57, 58
Pain Disability Index (PDI), 49, 59, 67, 70
diabetic neuropathy, 71
disability measure by, 70
Likert scale, 49
measuring items, 70
psychometrics, 70
RCTs, 71
scores validity, 71
spinal cord stimulation, 71
see also physical disability
Pain Discomfort Scale (PDS), 52
pain disorder, 250
diagnostic criteria, 250
pain empathy model, 238, 243
solicitous spouse responses, 242
verbal pain behavior, 242
pain expression scale, 173
pain expressions, cognitively impaired adult, 59
pain fear, 220
pain groups, 336
process group, 336
psycho-educational group, 336
types, 335
pain impact assessment, 50, 52, 53
adolescent pediatric tool, 57
BDI, 50
behavioural observation in adult, 59
BPI, 50
CHEOPS for children, 57
in children, 57
COMFORT scale for children, 57
FLACC for children, 57
GDS, 51
MBHI, 53
MPQ, 51
PASS, 51
PDI, 49
PDS, 52
PPPM for children, 57
RMDQ, 49
SF-36, 53
STAI, 51
TSK, 50
WHYMPI, 53
pain intensity, 438
anger internalization, 27
pain intensity assessment, 8
faces scales, 7
numeric rating scale, 7
verbal descriptor scales, 7
visual analog scale (VAS), 7
pain interference ratings, 67
sleep measure, 75
pain management, 8, 12, 46, 131, 472
aberrant drug-taking behaviors, 150
ACGME guidelines, 412
activities of daily living, 150
acute pain, 9
adverse events, 150
agencies involved, 416
analgesia, 150
“analgesic ladder” approach, 143
antidepressant, 259
anxiety, 192
APS’ role, 474
assessment, 7, 8
awareness creation, 253, 254, 333
barriers, 46, 411, 454
behavioral assessment, 172, 174
benign, 129
biofeedback, 209
pain management (cont.)
Biologics Control Act, 461
biopsychosocial model, 410, 411
CAM, 410
cancer, 9, 466
caregivers' participation, 364
catastrophizing, 50
CBT, 30, 186, 188, 454
CES, 205
chronic pain, 11, 466
clinical domains, 151
"clinical items", 46
clinical research issues, 263
co-disciplinary care, 412
cognitive impairment, 193
comfort–function model, 423
comorbid conditions, 135, 193
competency, 412, 413
coping strategies, 440
cortical stimulation, 204
cost of pain, 421
DEA, 462
depression, 191
drug efficacy, 139
at end of life, 135, 416, 465
evidence-based interventions, 455
factors, 4
frames of reference, 46
functional improvement, 9
gate control theory of pain, 410
Harrison Narcotic Act, 462
as human rights, 416, 417, 463
hypnosis, 208, 369
initiative, 459
interventional, 10, 203
issues, 439, 463
learning/conditioning behavioral model, 172
medication addiction, 119, 192
medication counseling, 334
medication selection, 135, 262
mind-body connection, 410
mind-body problem, 409
mind-body separation, 409
MPC, 421
neuromodulation, 201
non-pharmacologic therapy, 254, 473
non-physiological factors, 18
non-terminal pain medication, 135
non-verbal patients, 8
NOSE, 151
nursing in, 412
operant conditioning, 172, 176
opioids, 9, 137, 413, 461
overmedication, 418
PADT, 151
pain body diagram, 7
pain care, 416, 440
pain diary, 133, 334
pain management, 410
patient evaluation, 137
patient's activity levels, 335
patient's goals, 49
patient's role, 334
personality disorders, 193
physical therapy, 410
physician's role, 130
policy statement, 218
positive psychology, 336
postoperative pain, 8, 465
pseudoaddiction, 119
psychoactive adjuvant medications, 258
psychotherapeutic modalities, 255
PTSD, 192
quality indicator, 422
quality of, 422
rational polypharmacy, 414
record keeping, 133
research trends, 426
resources, 8
right to pain relief, 464
rTMS, 204
SAFE score, 153
self-management resources, 454
sensory specificity theory, 410
spinal pain, 283
TAS, 152
tDCS, 205
team, 194
treatment, 189, 253, 416, 418, 426, 463, 464
underreporting patient
web-based courses, 413
pain management, geriatric, 390, 394
associated conditions, 399
barriers, 397
discussing preferences, 400, 401
environmental constraints, 399
family in, 400
general reviews, 390
medication risks disclosure, 401
myths, 396, 399
non-pharmacologic treatments, 400
and obesity, 399
pain expectancies, 398
patient's choice, 397, 400
perception contradiction, 397
provider discomfort, 398
resources, 402
sleep disturbance, 399
systematic approaches, 401
treating depression, 400
pain management, legislation
abuse prevention, 420
California Business and Professional Code, 420
civilian health care, 419–20
Commonwealth of Massachusetts, 420
Conquering Pain Act of 350, 419
medical marijuana, 420–21
for military and veterans, 419
National Pain Care Act of 350, 419
state regulation status, 420
pain medicine, 1, 334, 410, 411
benefit, 334
practices, 1
pain myth, geriatric
aging as cause, 39
compromised with pain, 393
medicine as primary way, 393
worsens with age, 392
pain phases, 251
acute pain phase, 250
chronic pain phase, 251
pain predisposed personality
effects, 27
"migraine-personality", 27
"pain-prone personality", 27
"RA"-personality, 27
pain prevalence, 426
pain rehabilitation program
physical and occupational therapy, 381
single-blind trial, 381
pain rehabilitation, pediatric
behavioral health care, 382
leisure education and recreation therapy, 383
outcome assessment, 385
parent/family education, 383
school re-entry process, 385
subspeciality care, 382
therapies, 383
pain scales
dimensions, 68
faces, 7, 56
pain self-report, 58, 67
BPI for adult, 59
FPS for adult, 58
FPS-R for children, 56
GPM for adult, 59
Oucher for children, 56
patient diary for adult, 58
PDI for adult, 59
Pieces of Hurt tool for children, 56
VAS for children, 56
VRS for adult, 58
Wong-Baker FPS for children, 56
see also pain-related physical function
pain sensitivity, 447
COMT, 448
factors in, 448
GCH1, 448
genetic factors, 448, 449
heritability, 447
individual subsets, 448
Pain Stages of Change Questionnaire (PSOCQ), 55
pain symptoms, 20
human rights and pain treatment, 463
pain treatment, 54
adjuvant medications, 367
anticonvulsant drugs, 261
antidepressant, 260
ethical obligation, 55
MPRCQ, 55
NSAIDs, 367
opioids, 367
pharmacologic and psychotherapeutic, 262
PSOCQ, 55
steroids, 367
pain, geriatric
cognitive strategies, 395
coping strategies, 395
general reviews, 390
myths, 394
opioid usage, 393, 394
patient strategies, 394
sleep disruption, 393
PAINAD, see Pain Assessment in Advanced Dementia
Pain-Associated Disability Syndrome (PADS), 378
Bursch's criteria, 378
PAINE, 86
"pain-prone personality", 27
pain-related avoidance behavior, 380
pain-related fear
effects of, 97
see also anxiety; pain avoidance behavior
pain-related physical function
activity level, 67
BPI, 67
PDI, 67
perceived interference, 67
response biases, 67
scale selection, 67
SIP, 67
sleep, 67
WHYMPI, 67
see also pain interference; physical disability
pain-related sleep difficulties, 75
Chronic Pain Sleep Inventory, 75
measures, 75
responsivity, 76
summary ratings, 75
see also pain-related physical function
palliative care patient
adjustment disorders, 357
depressive disorder, 357
mood disorder types, 356
psychological assessment, 356
psychological tasks, 356
structured interview, 357
palliative care unit, 355
nursing homes, 356
palliative medicine, 355
goal, 358
methods in cancer pain, 366
NSAIDs, 367
opioids, 367
pain assessment, 356
scope, 355
steroids, 367
palliative patients
adjustment disorder prevalence, 360
anxiety disorder prevalence, 359
anxiety of pain, 359
attitude impact, 359
cancer pain, 365, 369
catastrophizing, 359
coping process, 356, 371
depth desire, 358
depth indicator, 358
demented patients, 362
demoralization, 360
denial, 363
depression, 358
distress, 358, 360, 361
fear of pain, 359
functional trajectories, 358
impaired cognition, 362
interventions for caregivers, 371
need of hope, 361
pain crisis, 372
pain education, 369
pain effects, 365
patient selection, 366
perceived stress, 366
preparatory grief, 361
psychotherapy, 371
PTSD impact, 359
with refractory pain, 372
and social factors, 363
spiritual pain, 361
suffering, 361
trauma impact, 359
palliative treatment
adjuvant medications, 367
emotional expressive therapy, 367
hypothesis, 369
psychotherapy, 369
panic disorder, 88
Parent's Postoperative Pain Measure (PPPM), 57
paresthesias, 276
partner-guided pain management, 240
partner-guided group, 241
PASS, see Pain Anxiety Symptom Scale
patient controlled analgesia (PCA), 9
patient management, geriatric
decision-making, 397
Patient-Reported Outcomes Measurement Information System (PROMIS), 76, 451
CAT, 451
uses, 451
Pavlovian B conditioning, 176
PBAT, see Pain Behavior Assessment Tool
PBC, see Procedure Behavior Checklist
PCA, see patient controlled analgesia
PD, see personality disorders
PDI, see Pain Disability Index
PDMPs, see prescription drug monitoring programs
PDS, see Pain Discomfort Scale
pediatric pain
biofeedback therapy, 239
CBT, 240
family based therapy, 240, 242
parental solicitousness, 237
peripheral nervous system (PNS), 274
peripheral sensitization, 274
see also central sensitization
persistent pain, see chronic pain;
psychogenic pain
personality disorders (PD), 90, 193
borderline, 90
diathesis-stress model, 192
see also somatoform pain disorder
PET, see positron emission tomography
pharmacological agents, 367
pharmacological standards of care
ACGME, 415
JCAHO, 415
non-governmental organizations, 415
opioid-related health issue, 414–15
rational polypharmacy, 414
stakeholders, 415
pharmacotherapy
adjuvants, 143
administration routes, 132
“analgesic ladder” approach, 143
analgesics combinations, 139
change in medication, 139
chronic pain, 133
dosage control, 139
drug efficacy, 139
evidence-based algorithm, 135
goal-oriented management plan, 136, 138
interventional procedures, 133
<table>
<thead>
<tr>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>pharmacotherapy (cont.) non-opioid medications, 179 opioids, 132 pain attenuation, 131 pain severity, 143 physical therapy, 132 phobia, 95 physical dependence, 144 physical disability assessment instruments, 68 physical examination, 278 physical performance, 74 measures, 74 measures responsibility, 74 RCTs, 75 validity, 74 physical therapy, 178, 410 physiological pain response, 167 physiological pain, see nociceptive pain &quot;placebo effects&quot;, 17, 18 analgesia, 18 back pain, 18 PMPs, see prescription monitoring programs PNS, see peripheral nervous system poker chip tool, 27 polypharmacy, 118 indications for, 137 POMS, see Profile of Mood States POPP, see pre-opioid prescribing period positive psychology, 336 positive reinforcement, 178 positron emission tomography (PET), 451 post-traumatic stress disorder (PTSD), 26, 88, 192 animal study, 88 case example, 88 see also traumatic events Post-Traumatic Stress Disorder (PTSD), 359 PPM, see Parent’s Postoperative Pain Measure Practice-Based Evidence for Clinical Practice Improvement Design (PBE-CPI), 452 pre-opioid prescribing period (POPP), 149 associated activities, 149 initiation phase, 149 preparatory grief, 361 prescription drug monitoring programs (PDMPs), 414 prescription monitoring programs (PMPs), 414 prescription principles, 134 Procedure Behavior Checklist (PBCL), 57 Profile of Mood States (POMS), 104 advantages, 104, 106 emotional functioning, 106 as function of pain treatment, 104 limitations, 106 mood dimensions, 104 validation, 104 see also self report progressive muscle relaxation, 176 progressive muscle relaxation therapy, 255 PROMIS, see Patient-Reported Outcomes Measurement Information System proton magnetic resonance spectroscopy (H-MRS), 451, 452 pseudoaddiction, 143, 144 pseudotolerance, 143 see also opioid therapy pseudotumor cerebri, see idiopathic intracranial hypertension (IIH) PSOCQ, see Pain Stages of Change Questionnaire psychiatric comorbidity abdominal pain, 87 addiction, 82 anxiety, 87 of arthritis pain, 83 categories, 82 of chronic spinal pain, 83 delusion, 82 depression, 86 incomplete evaluation of, 83 pain treatment difficulties, 82 panic disorder, 88 population studies, 84 post-traumatic stress disorder (PTSD), 88 see also diathesis-stress model psychiatric diagnosis DIS, 104, 105 SCID, 104, 105 unstructured interviews, 104 psychiatric disorders, 83, 84 anxiety, 87 as comorbidity, 350 depressive disorder model, 96 diagnosis, 96, 97 lifetime prevalence, 342 opioid treatment, 84 psychogenic pain, 5, 6, 249 &quot;psychological cures&quot;, 17 psychological disturbances, 102 psychological therapies, 317 psychological treatment, see behavioral treatment efficacy psychotherapy existential, 370 group therapy, 368, 371 individual therapy, 370 insight-oriented, 370 life review, 369 meaning restoration, 367 supportive, 370 psychotic disorders, 91 dementia, 91 schizophrenia, 91 psychotic drug effects, 2 PTSD, see post-traumatic stress disorder public health crisis, 409 punishment paradigm, 168, see also learning/conditioning behavioral model 168 QEEG, see quantitative EEG quantitative EEG (QEEG), 210 quaternary mirtazapine, 368 RA, see rheumatoid arthritis rACC, see rostral anterior cingulate cortex randomized clinical trials (RCTs), 70, 71 BPI, 70 cancer pain evaluation, 70 diabetic peripheral neuropathic pain (DPNP), 70 Fabry disease, 70 fibromyalgia, 70 magnetic field therapy, 71 neuropathic pain, 71 PDI, 71 physical performance, 75 SII, 72 WHYMPI, 74 randomized controlled trials (RCTs), 452 relaxation training, 319 RAP, see recurrent abdominal pain &quot;RA&quot;-personality, 27 rational polypharmacy, 414 RCTs, see randomized clinical trials; randomized controlled trials &quot;real-time&quot; functional MRI (rtfMRI), 33 rACC, 33 reboxetine, 259 recurrent abdominal pain (RAP), 377 rehabilitation cognitive shift on pain, 22 see also pain rehabilitation program; pain rehabilitation, pediatric reinforcement negative, 178 positive, 1205n, 178 reinforcement survey schedules, 173 reinterpretation, 225, 230 relaxation, 32 meditation, 33</td>
</tr>
</tbody>
</table>
Index

relaxation training, 319
REMS, see Risk Evaluation Mitigation Strategies
respondent conditioning, 30
effects, 171
fear, 26
rheumatoid arthritis (RA), 310
CBT, 319
DMARD, 311
economic impact of, 310
effect of pain, 314
FDA-approved Biologics, 311
laboratory testing, 311
prevalence, 310
SRTs, 319
symptoms, 310
treatment, 312
see also osteoarthritis (OA); systemic lupus erythematosus (SLE)
rheumatoid factor (RF), 310
right to pain relief, 464
as law antidote, 464
pain relief, 464
Risk Evaluation Mitigation Strategies (REMS), 10
RMDQ, see Roland Morris Disability Questionnaire
Roland Morris Disability Questionnaire (RMDQ), 49
rostral anterior cingulate cortex (rACC), 33
rtfMRI, see "real-time" functional MRI
rtTMS, see transcranial magnetic stimulation
SAFE score, 153
domains, 152
form, 152
green zone, 152
red zone, 153
yellow zone, 153
SARIs, see serotonin-2 antagonist/reuptake inhibitor
SCID, see Structured Clinical Interview for DSM
SCL-90R, see Symptom Checklist – 90 Revised
Screener and opioid assessment for patients with pain (SOAPP), 153, 154
Screening instrument for substance abuse potential (SISAP), 153
S-CST, see spouse-assisted coping skills training
SE, see self-efficacy
SEGT, see supportive-expressive group therapy
selective serotonin and norepinephrine reuptake inhibitor (SSNRI), 333
duloxetine, 332
venlafaxine, 332
self-care, 125
self-efficacy (SE), 23, 24, 366, 371
function of, 24
judgments, 23
psychological processes, 24
ratings, 24
self-regulatory treatments (SRTs), 255, 317
arthritus, 319
see also biopsychosocial model; cognitive-behavioral therapy (CBT)
sensory focus, 224
catastrophizing, 224
desire for control, 224
experimental pain studies, 223
fear of pain, 223
gender variables, 223
mindfulness-based strategies, 223
moderating variables, 224
research studies, 222
threat expectancy, 223
treatment outcome, 222
sensory specificity theory, 410
serotonin norepinephrine reuptake inhibitor (SNRI), 132, 281, 367
duloxetine, 259, 281, 345, 368
milnacipran, 259
venlafaxine, 259, 281, 345, 368
see also antidepressant
serotonin specific reuptake inhibitor (SSRI), 280, 281, 367
advantages, 260
citalopram, 259
effect on CNS, 280
escitalopram, 259
fluoxetine, 259
fluvoxamine, 259
mirtazapine, 368
paroxetine, 259
sertraline, 259
side effects, 260, 280
see also antidepressant
serotonin-2 antagonist/reuptake inhibitor (SARI), 281
see also antidepressant
SF-36, 104
Cronbach's alpha, 103
perceived health status, 103
scales, 103
validation, 104
shaping procedure, 169
see also learning/conditioning
behavioral model
shingles, see herpes zoster
sick role behavior, 386
chronic pain, pediatric, 379
functional disability, 380
psychosocial model, 379
sickle cell anemia
pain management, 5
Sickness Impact Profile (SIP), 71
physical functioning scale, 72
psychometrics, 72
RCTs, 72
scales, 72
summary scores, 71
validation, 72
SHL, see spontaneous intracranial hypotension
SIP, see Sickness Impact Profile
SISAP, see Screening instrument for substance abuse potential
SLE, see systemic lupus erythematosus
sleep hygiene counseling, 335
SNRI, see serotonin norepinephrine reuptake inhibitor
SOAPP, see screener and opioid assessment for patients with pain
socio-demographic factors, 434
diversity, 436, 437
in pain management, 440, 441
vulnerable populations, 434
woman physician, 437
somatic pain, 6, 249
somatisation, see sensory focus
somatoform pain disorder, 83, 90, 250
case example, 89
comorbidity of, 90
reinforcement, 89
studies on, 90
see also anxiety; pain disorder
SOPA, see Survey of Pain Attitudes
spinal anatomy, 274
CNS, 274
lumbar motion segment, 272
spinal cord, 274
vertebrae, 273
spinal pain
epidemiology, 271
management, 283
origin, 271
pathophysiological factors, 275
patient evaluation, 277
patterns and diagnosis, 276
pharmacologic approach, 279
treatment, 278, 283
see also back pain
spiritual pain, 361
factors affecting, 361
spontaneous intracranial hypotension (SH), 341
spouse response inventory, 173

© in this web service Cambridge University Press

www.cambridge.org
spouse-assisted coping skills training (S-CST), 241, 245
insight-oriented therapy, 241
partner-guided group, 241
partner-guided pain management, 240
SRT, see self-regulatory treatments
SSRI, see selective serotonin and norepinephrine reuptake inhibitor
SSRI, see serotonin specific reuptake inhibitor
“stages of change” model, 335
action, 335
contemplative, 335
maintenance and relapse prevention, 335
precontemplative, 335
preparation, 335
STAI, see State-Trait Anxiety Inventory
“state”, 95
State-Trait Anxiety Inventory (STAI), 51, 95, 97, 106
stenosis, 272
“Stepped Care” approach, 189
pain management, 189
patient concerns, 189
psychoeducational programs, 189
steroids, 367
dexamethasone, 368
osteopenia, 133
prednisone, 368
side effects, 368
stimulants, 258
methylphenidate, 368
opioids, 368
side effects, 368
stimulus generalization, 20, 166
see also learning/conditioning; behavioral model
“stress-tension hyperactivity-pain” model, 291
Structured Clinical Interview for DSM (SCID), 104, 105
substance abuse, 84, 192
case example, 88
disorders, 119
management, 119
see also opioid therapy
suffering, 361
supportive psychotherapy, 370
supportive psychosocial interventions, 367
supportive-expressive group psychotherapy (SEGT)
therapists’ task, 371
supraspinal pain response, 167
suppression, 230
Survey of Pain Attitudes (SOPA), 54
pain beliefs, 54
sub scales, 54
validity, 54
Symptom Checklist – 90 Revised (SCL-90R), 103
systemic lupus erythematosus (SLE), 312
awareness creation, 313
azathioprine, 313
chronic pain treatment, 314
cyclophosphamide drug, 313
cyclosporine A, 313
DMARDs, 313
drug treatment, 314
and fibromyalgia, 314
impact, 312
methotrexate’s elimination, 313
pathophysiology, 312
and pregnancy, 313
prevalence, 312
screening tests, 313
symptoms, 312
see also osteoarthritis (OA); rheumatoid arthritis (RA)
Tampa Scale of Kinesiophobia (TSK), 50, 98
tampering, 160
see also extractability; substance use
TAS, see Translational Analgesic Score
TCAs, see tricyclic antidepressants
tDCS, see transcranial Direct Current Stimulation
tDTS-Fentanyl, see transdermal fentanyl system
temporal summation activity, 449
temponomandibular disorder (TMD)
predictor, 449
tender points (TPs)
FMS, 288
tension myalgia, 290
Tension-Anxiety, 104
therapeutic plan
biopsychosocial approach, 2
evidence based components, 2
thought pain response, 167
thought suppression, 216
threat expectancy effect, 223
time-based pacing, 186
tolerance, 144
topical
capsaicin, anesthetics, 332
lidocaine, analgesic, 332
touch therapy, 410
“trait”, 95
tramadol, 144
transcranial Direct Current Stimulation (tDCS), 205
mechanism, 204
transcranial magnetic stimulation (rTMS), 204
in cortex, 204
efficacy, 204
protocol, 204
working principle, 204
transdermal fentanyl system (TDS-Fentanyl), 161
Translational Analgesic Score (TAS), 152
traumatic events, 26
tricyclic antidepressants (TCAs), 74, 76, 132, 258, 280
adverse effects, 260
amitriptyline, 259, 332, 368
clo mipr amine, 259
desipramine, 259, 332
doxepin, 332
imipramine, 259, 368
neuropathic pain, 280
nortriptyline, 267, 268, 368
side effects, 368
see also antidepressant
trigeminal autonomic cephalgia, 79
see headaches, cluster
trigeminal neuralgia, 329
alldynia, 329
pain in, 329
TSK, see Tampa Scale of Kinesiophobia
UBA pain behavior scale, 173
UDT, see urine drug testing
unconditioned response (UR), 166
see also learning/conditioning; behavioral model
unconditioned stimulus (US), 166
aversive, 166
see also learning/conditioning; behavioral model
UR, see unconditioned response
urine drug testing (UDT), 160
compliance testing, 155
factors considered, 157
forensic testing, 155
interpretations, 160
limitations, 159
US, see unconditioned stimulus
US–UR association, 166
see also learning/conditioning; behavioral model
varicella zoster virus (VZV), 7
VAS, see visual analog scale
venlafaxine, 132
verbal descriptor scales (VDS)
see (verbal rating scales)
<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
<th>Detailed Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>verbal rating scale (VRS)</td>
<td>48, 58</td>
<td></td>
</tr>
<tr>
<td>vertebrae</td>
<td>272, 273</td>
<td></td>
</tr>
<tr>
<td>articular processes</td>
<td>273</td>
<td></td>
</tr>
<tr>
<td>discs</td>
<td>272</td>
<td></td>
</tr>
<tr>
<td>foramen</td>
<td>272</td>
<td></td>
</tr>
<tr>
<td>intervertebral discs</td>
<td>274</td>
<td></td>
</tr>
<tr>
<td>lamellae</td>
<td>274</td>
<td></td>
</tr>
<tr>
<td>lamina</td>
<td>272</td>
<td></td>
</tr>
<tr>
<td>ligaments</td>
<td>272</td>
<td></td>
</tr>
<tr>
<td>nucleus pulposus</td>
<td>274</td>
<td></td>
</tr>
<tr>
<td>stenosis</td>
<td>272</td>
<td></td>
</tr>
<tr>
<td>Vigor-Activity</td>
<td>104</td>
<td></td>
</tr>
<tr>
<td>visceral pain</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>visual analog scale (VAS)</td>
<td>7, 48, 56</td>
<td></td>
</tr>
<tr>
<td>VRS</td>
<td></td>
<td>see verbal rating scale</td>
</tr>
<tr>
<td>VZR</td>
<td></td>
<td>see varicella zoster virus</td>
</tr>
<tr>
<td>wait-list</td>
<td></td>
<td>control condition, 184</td>
</tr>
<tr>
<td>“well behaviors”</td>
<td>19, 124, 165, 180</td>
<td>facilitative responses, 237</td>
</tr>
<tr>
<td>see also pain behaviors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>West Haven-Yale Multidimensional Pain Inventory (WHYMPI)</td>
<td>53, 72</td>
<td>factor structure analysis, 73</td>
</tr>
<tr>
<td>general activity subscale, 73</td>
<td></td>
<td></td>
</tr>
<tr>
<td>perceived Interference scale, 73</td>
<td></td>
<td></td>
</tr>
<tr>
<td>psychometric properties, 73</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RCTs, 74</td>
<td></td>
<td></td>
</tr>
<tr>
<td>responsivity, 74</td>
<td></td>
<td></td>
</tr>
<tr>
<td>suffering, 73</td>
<td>validation, 74</td>
<td></td>
</tr>
<tr>
<td>WHO-ICE</td>
<td>450</td>
<td></td>
</tr>
<tr>
<td>see also World Health Organization</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WHYMPI, see West Haven-Yale Multidimensional Pain Inventory</td>
<td></td>
<td></td>
</tr>
<tr>
<td>windup (WU)</td>
<td>449</td>
<td>sensitivity, 291</td>
</tr>
<tr>
<td>see also temporal summation activity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WL, see wait-list</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wong-Baker FPS</td>
<td>56</td>
<td></td>
</tr>
<tr>
<td>World Health Organization (WHO) ICE, 450</td>
<td></td>
<td></td>
</tr>
<tr>
<td>in pain care, 415</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WHO-ICE, see windup (WU)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zung SDS, see Zung Self-rating Depression Scale</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zung self-rating depression scale (Zung SDS)</td>
<td>100</td>
<td>Cronbach’s alpha, 100</td>
</tr>
</tbody>
</table>